Schedule 13D ownership disclosure
COCRYSTAL PHARMA INC
Common Stock, par value $0.001 per share · CUSIP: 19188J409
Event date: 2026-11-04
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- OPKO HEALTH, INC.Reported CIK 0000944809
Shares: 5,692,916.00 · Class: 29.6%
- FROST PHILLIP MD ET ALReported CIK 0000898860
Shares: 2,788,106.00 · Class: 13.9%
- Frost Gamma Investments TrustReported CIK 0001380896
Shares: 2,712,977.00 · Class: 13.6%
- Rubin Steven DReported CIK 0001381874
Shares: 75,872.00 · Class: 0.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000944809-26-000003
- Form type
- SCHEDULE 13D/A
- Filer
- Cocrystal Pharma, Inc.
- CIK
- CIK 1412486
- Filed
- Nov 06, 2026
- Reporting period
- Nov 04, 2026
- Description
- Schedule 13D beneficial ownership